TY - JOUR
T1 - EP14.02-00 Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer
AU - Schwendenwein, A.
AU - Boettiger, K.
AU - Kovacs, I.
AU - Barany, N.
AU - Megyesfalvi, Z.
AU - Grusch, Michael
AU - Kowol, Christian
AU - Rezeli, M.
AU - Hoetzenecker, K.
AU - Dome, B.
AU - Schelch, Karin
N1 - Accession Number: WOS:000858678101409
Manuelle Eingabe
PY - 2022/9
Y1 - 2022/9
N2 - Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is associated with a poor survival rate. SCLC is a tremendously lethal disease characterized by rapid growth and a high propensity to metastasize. Hitherto, platinum-based chemotherapy is one of the key components of the standard first-line therapeutic regimen of SCLC. Despite the known initial chemosensitivity of SCLC, the prospect of therapeutic success is limited by early relapse and acquired resistance in almost all patients. In recent years, only little progress has been made in the management of the disease although considering the addition of immunotherapy to the therapeutic armamentarium. Entinostat, a class I histone deacetylase inhibitor (HDACi), has been reported to exhibit anti-cancer effects in various human cancers. Entinostat has been demonstrated to synergize with cisplatin and moreover reverses cisplatin resistance. In this study, we investigated the combined effect of cisplatin and entinostat in SCLC with the aim to determine the mechanisms behind differential responses to the combination treatment using proteomic data.
AB - Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is associated with a poor survival rate. SCLC is a tremendously lethal disease characterized by rapid growth and a high propensity to metastasize. Hitherto, platinum-based chemotherapy is one of the key components of the standard first-line therapeutic regimen of SCLC. Despite the known initial chemosensitivity of SCLC, the prospect of therapeutic success is limited by early relapse and acquired resistance in almost all patients. In recent years, only little progress has been made in the management of the disease although considering the addition of immunotherapy to the therapeutic armamentarium. Entinostat, a class I histone deacetylase inhibitor (HDACi), has been reported to exhibit anti-cancer effects in various human cancers. Entinostat has been demonstrated to synergize with cisplatin and moreover reverses cisplatin resistance. In this study, we investigated the combined effect of cisplatin and entinostat in SCLC with the aim to determine the mechanisms behind differential responses to the combination treatment using proteomic data.
M3 - Meeting abstract/Conference paper
SN - 1556-0864
VL - 17
SP - S537-S537
JO - Journal of thoracic oncology
JF - Journal of thoracic oncology
IS - 9
ER -
